Landos Biopharma, Inc(NASDAQ:LABP) 
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative col...
Website: http://landosbiopharma.com
Founded: 2017
CEO: Josep Bassaganya-Riera
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2023-11-24
P
O 4.32
H 4.80
L 4.32
C 4.75
V 4,928
10EMA 4.75
20EMA 4.75
60EMA 4.75
120EMA 4.75
250EMA 4.75